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Abstract
DNA vaccines (nucleic acid vaccines) have been gaining importance as promis-
ing therapeutics against infectious diseases, cancer, autoimmune disorders and 
allergy for the past two decades. However, the immune responses elicited by 
the DNA vaccines are not at the desired level to stimulate a protective immune 
response. Thus, studies are focused on the enhancement of DNA vaccine-induced 
immune response by different approaches. The most common approach is to use 
biomaterial-based adjuvants for enhanced antigen delivery and uptake by antigen-
presenting cells. Some of these adjuvants are alum, saponins, microspheres, 
nanoparticles, liposomes, polymers, etc. used in vaccine formulations. In addition, 
molecular adjuvants like cytokines, chemokines and heat shock proteins have been 
shown to be promising in designing DNA vaccines. In this chapter, molecular adju-
vants to improve DNA vaccination-induced immune responses will be summarized 
with a special focus on Bcl-xL anti-apoptotic protein.
Keywords: DNA vaccine, molecular adjuvant, delivery systems, antigen-presenting 
cells, Bcl-xL anti-apoptotic protein
1. DNA vaccine
DNA vaccine is a third-generation vaccine, which encompasses a vector with 
eukaryotic cell promoter, and a gene, which encodes for an immunogenic protein. 
These vaccines have been shown to elicit a robust cytotoxic T cell in comparison 
with subunit vaccines. Also, DNA vaccine has the capacity to induce both cellular 
and humoral immune responses by utilizing MHC I and MHC II antigen presen-
tation by DCs [1–3]. Although DNA vaccines are licensed for use in veterinary 
vaccines since 2005, they have their own limitation due to low transfection effi-
ciency. As a result, they perform poorly in human clinical trials and require multiple 
booster doses to achieve desirable immune response [2, 4, 5]. With the advent of 
new adjuvant systems such as nanoparticles, the immunogenicity of DNA vaccines 
can be enhanced considerably [1]. DNA vaccines are being currently used against a 
wide variety of infectious diseases as well as cancer [3].
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1.1 Antigen presentation to T lymphocytes
Surface receptors of T lymphocytes interact with antigens to mount an immune 
response [6]. For the antigenic features; alienation, molecular weight, the delivery 
route to the organism is very important. At the molecular level, these receptors 
interact with the phagocyte cell or infected target cell, which carries antigen on its 
surface bound to the major histocompatibility complex (MHC). While T cells do not 
recognize natural antigens, antigens must first be processed by antigen-presenting 
cells (APCs) and then presented to the T cells with the relevant MHC protein. 
T cells (cytotoxic T cells—Tc) with CD8 (cluster of differentiation 8) receptors 
recognize MHC I antigens, while T cells (helper T cells—Th) with CD4 receptor rec-
ognize antigens on MHC II. Macrophages are the first identified antigen-presenting 
cells. Then, dendritic cells and B cells were identified. T-cell receptors (TCRs) are 
proteins that have spread through the membrane extending from the cell surface to 
the outer periphery. Each cell carries thousands of the same receptor surface. TCRs 
recognize and bind only bound peptide antigens on MHC [7, 8].
1.1.1 Major histocompatibility complex (MHC)
MHC proteins are encoded by the respective gene in the genome of all the 
vertebrate animals. The human MHC proteins are called human leukocyte antigens 
(HLAs) (human MHC I antigens, HLA-A, B and C, human MHC II antigens, 
HLA-DR, DQ and DP). Because of the difference in MHC proteins between the 
tissue donor and recipient, they were first discovered with tissue transplant rejec-
tion. Even within a species, these proteins are not structurally the same because of 
differences in amino acid sequences, also known as polymorphisms. For this reason, 
it forms an important antigenic barrier in organ transplantation. MHC genes 
encode two classes of MHC proteins, class I and class II. While MHC class I protein 
is located on the surfaces of all the nucleated cells, MHC class II protein is located 
only on the surface of antigen-presenting cells (APCs), including B lymphocytes, 
macrophages and dendritic cells. The structure of the MHC I protein comprises of 
a relatively small size of the β-2 microglobulin protein with α1, α2 and α3 domains 
linked to each other by disulfide bonds. The α1 and α2 domains constitute the 
variable antigen-binding domain. MHC II protein is formed by α1, β1, α2 and β2 
domains, each of which is attached to one of the non-covalent bonds, and α1 and β1 
domains constitute the antigen-binding domain, which is a variable part [7, 9, 10].
MHC proteins carry proteins in the cell which they are in, on themself. Thus, if 
the cell is not infected, it will carry its own peptides on the MHC proteins. On the 
other hand, if the cell harbors a foreign pathogen or protein, it will contain foreign 
peptides on MHC proteins. The function of these MHC proteins is to allow T cells 
to recognize foreign antigen. The T cells constantly control the surface of other cells 
for foreign antigen presence and do not recognize foreign antigens unless they are 
presented through MHC proteins. No T cell interacts with MHC on a healthy cell 
surface, and self-attacking cells are eliminated during the development of tolerance. 
During antigen presentation, the MHC and peptide complex come out of the cell 
membrane and thus are recognized by the T cells. There are two different antigen 
presentations to T cells, MHC I and MHC II antigen presentation [7–9].
1.1.2 Antigen presentation via MHC I protein
Peptides that are processed endogenously in the cytoplasm of non-phagocytic 
cells are presented with MHC I proteins. These antigens are derived from viruses 
or intracellular pathogens that infect cells, also known as internal antigens. In this 
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pathway, for example, in a virus-infected cell, virus-associated proteins are primar-
ily digested in the cytoplasmic proteasome. Peptide antigens of about 10 amino 
acids are delivered to the endoplasmic reticulum (ER), and a pore protein (TAP) 
produced by the two proteins acts in this stage. The peptides are bound to the MHC 
I protein, which results in the chaperone protein, which retains the MHC protein at 
that site. The resulting complex is released from the ER and goes to the cell surface 
and integrates into the membrane. This complex is recognized and bound by 
cytotoxic T cells. The CD8 receptor on the Tc cell surface strengthens it by adding 
the binding complex. This binding allows cytotoxic T cells to produce perforin and 
cytotoxic proteins that kill infected cells [7, 8, 10, 11].
1.1.3 Antigen presentation via MHC II protein
The MHC II protein is produced only in cells that present phagocytic antigen. For 
example, if an extracellular pathogen such as a bacterium is engulfed and then pep-
tide antigens are provided, then MHC II proteins are produced in the ER and accu-
mulated therein blocked with Li proteins, which inhibit binding with other peptides. 
The MHC II-Li protein complex is transferred to lysozyme and then combined with 
the phagosome to form the phagolysosome. There are foreign pathogen antigens, 
pathogenic proteins including connective chaperones are digested to form peptides of 
10–15 amino acids. The resulting pathogenic peptides are transferred to the cell sur-
face by binding with MHC II. This complex is recognized by the TCR on the helper T 
cells; the CD4 coreceptor also binds to this complex and, through interaction with the 
Th cells, activates to produce cytokines. The produced cytokine activates antibody 
production by specific B-cell clones or causes inflammation [7, 8, 11].
1.2 Advantages and disadvantages of DNA vaccination
The structure of plasmid DNA provides an advantage over other traditional 
protein-based or carbohydrate-based grafts in which it inherently possesses DNA 
vaccination. Immunogenesis from DNA vaccination takes a long time, and there 
is no pathogenicity caused by inactivated virus in DNA vaccines. The vaccine 
containing plasmid DNA (pDNA) can encode many immunogenic proteins of the 
same virus and can also encode similar proteins belonging to different infective 
agents [12]. Another important advantage is that the production of DNA vaccines 
is easier when compared to recombinant protein vaccines [13]. DNA vaccines 
prepared to make the cytokines more desirable to direct the immune system are 
more potent and suitable for stimulating the type of immunological response by 
cloning genes encoding the target cytokine and antigens into the same expression 
plasmids. DNA vaccines lead to sustained stimulation of antigen expression and 
the immune response leading to prolonged protective immunity [7]. Easy con-
struction and manipulation of plasmid DNA are another important advantage of 
DNA vaccines [14].
DNA vaccines are stable at room temperature, are easy to obtain, are economi-
cal and are relatively more reliable than other vaccines. Plasmid DNA vaccines 
have been shown to be highly evaluated, safe and immunogenic in human clinical 
trials, even though they have no mental status [15]. However, it is necessary to 
increase transfection efficiencies of naked DNA vaccines, facilitate intracellular 
uptake, target into cells, and perform these operations with small amounts of 
DNA. Various gene delivery systems and adjuvant systems in the nanosphere are 
used to overcome these problems. During the use of nanotechnological adjuvant 
systems, the degradation of DNA is prevented, resulting in ultra-rapid delivery by 
targeting to desired cells [9, 16].
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2. Delivery systems for DNA vaccine
2.1 Viral gene delivery systems
Viral-based gene delivery systems are carriers on which modifications are made 
to transfer therapeutic genes to target cells without creating viral disease. Viral 
gene carriers such as adenoviruses, adeno-associated viruses, lentiviruses and 
retroviruses exhibit an effective ability to transfer genetic material to the target 
cell with high gene transfer efficiency [17–19]. In viral gene delivery systems, the 
transferred genetic material either remains an episomal element or is integrated 
into the host chromosome. Desired genetic placement leads to persistent and 
stable protein expression but increases with the introduction of oncogenic poten-
tial mutagenesis [18, 20]. In addition, viral vectors being targeted to specific cell 
types, the limited availability of DNA, and the laborious and expensive large-scale 
production have led to a growing disincentive for the development of non-viral 
gene carriers. The safety risk is lower for non-viral carriers compared to viral gene 
carriers [18, 21–24].
2.2 Non-viral gene delivery systems
2.2.1 Physical delivery systems
Physical gene transfection delivery systems are consisting of Non-viral gene 
delivery systems are in which pDNA is usually applied alone, which involves 
mechanical processes such as microinjection, biojector, pressure and particle bom-
bardment (gene gun), ultrasound, magnetofection, photoporation (laser assisted), 
hydroporation (hydrodynamic forced), droplet-based microfluidic platforms for 
in vitro transfection and electrical processes such as electroporation [10, 11, 21, 23, 
25]. In addition, ultrasound and microbubble-mediated plasmid DNA uptake is a 
fast, global and multi-mechanisms involved process [26, 27].
2.2.1.1 Microinjection
In microinjection, cell membrane or nuclear membrane is penetrated by simple 
mechanical force using a microneedle diameter of 0.5–5 μm, at a specific and 
reproducible depth with less physical pain than conventional DNA delivery. This 
gene delivery system is mainly used to inject DNA constructs in vivo. Application 
of DNA by this method leads to constant expression of the antigen encoded in the 
skin. This method can also be used to deliver DNA for a prolonged period of time, 
similar to the administration of drugs at a constant rate. In the method, usually 
the stratum corneum and the viable epidermis are breached by microneedles, after 
which DNA can be delivered into the dermis. There are several different micronee-
dle methods for DNA delivery; solid microneedles can be coated with DNA prior 
to skin penetration, uncoated microneedles can be used to damage the epidermis 
prior to application of a transdermal patch containing the DNA of interest, solid 
microneedles constructed with biopolymers can be coated with DNA such that the 
needles dissolve upon contact with the fluid in the dermis to release DNA into the 
skin and hollow microneedles can deliver DNA into the dermis through the needles 
[28–30]. Quantitative introduction of multiple components into the same cell is 
an advantage of this technique, while technical skills are required to prevent cell 
damage [31].
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2.2.1.2 Gen gun
The ballistic DNA delivery or DNA-coated particle bombardment (gene gun) 
that was first used for gene transfer to plants in 1987 uses heavy metal micropar-
ticles (e.g., gold, silver microparticles or tungsten, 1–5 μm in diameter) to hold 
nucleic acids and penetrate the target cells. Momentum allows penetration of these 
particles to a few millimeters of the tissue and then cellular DNA release. Gas pres-
sure, particle size and dose frequency are critical factors in determining the degree 
of tissue damage and penetration effectiveness of the application [18, 28]. This 
method has various advantages such as safety, high efficiency against parenteral 
injection, total amount of DNA required for delivery is low, no receptor is required, 
size of DNA is not a problem and production of DNA-coated metal particles is easy 
to generate. A major disadvantage is that it induces greater immune responses than 
microinjection due to tissue damage with intradermal delivery, even in low doses, 
and also, gene expression is short term and low. This technique is a widely tested 
method for intramuscular, intradermal and intratumoral genetic immunization. 
The use of gene gun for gene therapy against various cancers in clinical trials has 
also been demonstrated [18, 28–30].
2.2.1.3 Biojector
This device is commonly used to deliver medications through the skin for 
intradermal, subcutaneous and intramuscular applications. Usually, CO2 pressure 
is used to force medications (e.g., vaccine) loaded in the device through a tiny 
orifice, which creates a high-pressure stream capable of penetrating the skin in the 
absence of a needle [28–30]. Biojectors have been used to deliver different kinds 
of vaccines such as DNA vaccine, in preclinical studies and human clinical trials to 
elicit significantly higher antibody responses and cell-mediated immunity (CMI) 
to the conventional (needle and syringe) vaccine delivery systems [29]. Because 
biojector-based delivery systems can increase the uptake of DNA in tissues of the 
skin and muscle, efficacy of the DNA vaccine is considerably increased. In a phase 
1 trial for HIV vaccine, the success demonstrated with biojector used to enhance 
the efficiency of DNA transfection coupled with the fact that biojectors do not use 
needles that will most likely lead to the increased use of biojectors for DNA delivery 
in the clinic [28–30].
2.2.1.4 Electroporation
Electroporation was first studied on the degradation of cell membrane with 
electric induction in the 1960s. The first reported study is transfection of eukaryotic 
culture cells through electroporation in 1982 [18, 28]. In many subsequent studies, 
transfection was performed on animal and plant cells via electroporation [18]. This 
physical gene delivery technique uses electrical pulse to generate transient pores in 
the cell plasma membrane allowing efficient transfer of DNA into the cells. Pore 
formation occurs very rapidly, in approximately 10 ns. The size of the electric pore 
is estimated to be smaller than 10-nm radius. If the molecule is smaller than the 
pore size (as in oligonucleotides and chemical compounds), it can be transferred to 
the cell cytosol through diffusion [18, 28]. This method has been effectively applied 
in humans in order to enhance gene transfer and tested in several clinical trials 
such as prostate cancer [28, 30], leukemia [28], colorectal cancer [28], malignant 
melanoma [28, 30], brain carcinomas [28], Parkinson’s disease [28], Alzheimer’s 
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disease [28] and depression [28]. When the parameters are optimized, this method 
is equally effective as viral vectors for in vivo application. But, the disadvantage is 
that it often results in a high incidence of cell death because of high temperature due 
to high voltage application. And also, transfection of the cells in large regions of the 
tissues is difficult [18, 28–30].
2.2.1.5 Ultrasound
Ultrasound (US) is a promising tool for gene delivery that has been able to facili-
tate DNA transfection of cells. US-mediated delivery is of interest due to its potential 
for repeated application, organ specificity, broad applicability to acoustically acces-
sible organs, low toxicity and low immunogenicity. Different kinds of studies have 
examined gene transfection in various types of cells in vitro and with various organs 
and tissues in vivo, including brain [26, 30], cornea [30], pancreas [30], skeletal 
muscle [26, 30], liver [26, 30], heart [26, 30] and kidney [26, 30]. The advantages are 
that only acoustic energy is introduced into the cellular environment, which avoids 
possible safety concerns associated with chemical, viral or other materials intro-
duced and left behind by other methods. Also, US-mediated delivery has been seen 
in many kinds of cell types and so may be broadly applicable, in contrast to other 
methods that often require reformulation for specific cell types. Unlike chemical 
delivery systems, US-mediated DNA uptake is often shown to be non-endocytotic. 
Acoustic cavitation plays a major role in the cell membrane permeabilization that 
facilitates DNA uptake. US can possibly deliver plasmid DNA to the periphery of the 
cell nucleus and facilitate rapid transfection by altering the cytoskeletal network. 
However, US-based gene transfection studies are still in preclinical trials and have 
the major challenge of relatively low transfection efficiency compared to optimal 
complexed chemical formulations and viral gene delivery systems [26, 28, 30].
The use of ultrasonication with the microbubble technique has shown great 
potential for intracellular gene delivery. The microbubble-cell membrane interac-
tion serves as the key element bridging the acoustic conditions and the endpoint 
delivery outcomes. However, since the fundamental mechanical question of how 
plasmid DNA enters the intracellular space mediated by ultrasound and micro-
bubbles is not fully understood, gene transfection efficiency is much lower than the 
potential for large-scale clinical needs [26, 27]. In one study, the gene transfection 
of human prostate cancer cell line (DU145) with fluorescently labeled DNA (pDNA 
gWiz-GFP) was studied after ultrasound exposure. In this process, different 
sonication conditions have been studied. DNA uptake, location of DNA during its 
intracellular trafficking and gene transfection efficiency after ultrasound exposure 
were followed for various periods by confocal microscopy and flow cytometry. As a 
result, ultrasounds delivered DNA into cell nuclei shortly after sonication and that 
the rest of the DNA cleared by autophagosomes/autophagolysosomes [26]. Also, 
ultrasound application combined with microbubbles has shown good potential for 
gene delivery. In one study, to unveil the detailed intracellular uptake process of 
plasmid DNA stimulated by ultrasound and microbubbles, the role of microbubbles 
in this process was investigated. So, targeted microbubbles were used to apply 
intracellular local stimulation on the cell membrane, and high-speed video micro-
scopic recordings of microbubble dynamics were correlated with post-ultrasound 
3D fluorescent confocal microscopic images fixed immediately after the cell. Two 
ultrasound conditions (high pressure, short pulse and low pressure, long pulse) 
were chosen to trigger different plasmid DNA uptake routes. Results showed that 
plasmid DNA uptake evoked by localized acoustically excited microbubbles was 
a fast (<2 min), global (not limited to the site where microbubbles were attached) 
and multi-mechanisms involved process [27].
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2.2.2 Chemical adjuvant systems
The term adjuvant is derived from the Latin word “adjuvare” which means 
“help” or “develop.” Adjuvants are used to increase the life, quality and degree of the 
specific immune response developed against the antigens. At the same time, they 
have low toxicity and are capable of sustaining the immunological activity alone by 
inhibiting polymer accumulation in the cell [11, 32, 33]. So, they are preferred in 
vaccinations for newborns or adults. Also, they can stimulate a long-term immune 
response by reducing the amount of antigen that must be given in a single dose of 
vaccine [9, 34].
Adjuvants are classified according to the source of their constituents, their 
physicochemical properties or their mechanism of action and are generally grouped 
into two subheadings. One of them is molecular adjuvants that are immunostimu-
lants (and also genetic adjuvants) (e.g., TLR ligands, cytokines, saponins and 
bacterial exotoxins that stimulate the immune response) and act directly on the 
immune system to enhance immune response against antigens. The other one is 
carrier systems; they are systems that promote vaccine antigens in the most appro-
priate way to the immune system while also exhibiting controlled release and depot 
effects, thereby increasing the immune response (e.g., mineral salts, emulsions, 
liposomes, virosomes, biodegradable polymer micro/nano particles and immune 
stimulating complexes—ISCOMs) [1, 9, 11, 34–39].
Cytokines can also be delivered directly with the DNA vaccine, either on the 
same or on a separate expression plasmid as adjuvant duty. The effects of plasmid 
encoding cytokines such as interleukin IL-10, IL-12 or IFN-γ together with DNA 
vaccines have been studied in a variety of animal and disease models, up to clinical 
trials in humans [38]. Also, various studies describe the usage of plasmids coding 
for immune-signaling molecules, either as partial or as full-length genes. Many 
adjuvants function by activating the innate immune system via binding to Toll-like 
receptors (TLRs). Another innate immune mechanism, which is being explored 
for improving DNA vaccination, is the sensing of viral infections via pathogen 
recognition receptors (PRRs). Both proteins detect the presence of viral RNA in the 
cytosol. Co-delivery adjuvants with the vector coding for antigenic proteins result 
in significantly higher antibody titers as compared to the non-adjuvanted controls. 
Other strategies for genetic adjuvants include components of the complement 
system, protein aggregation domains, chemokines or co-stimulatory molecules. 
Whereas DNA vectors encoding certain cytokines have already entered clinical test-
ing in humans, studies with many other genetic adjuvants were mostly performed 
in mice. Therefore, these promising studies should be optimized into powerful 
strategies to boost DNA vaccines in more complicated animals and humans [38].
Adjuvants can easily be internalized by the antigen-presenting cells (APCs) 
(macrophages and dendritic cells) because of their size being similar to pathogens 
(<10 μm) [11, 22, 25, 40]. The internalization and presentation of the adjuvant 
depends on the chemical and physical properties of the adjuvant system. It has 
been shown in various studies that the particles with cationic properties are more 
efficiently taken up by macrophages and dendritic cells [21, 24, 25, 41–43].
The characteristics that should be present in the adjuvants can be listed as fol-
lows: stability in an acidic, basic and enzymatic environment; retention of retained 
antigen or nucleic acid by constant release; systemic and mucosal immunity being 
effectively induced and balance between effective immunity and immunological 
tolerance at high doses [9, 44]. Also, the immunogenicity of weak antigens should 
increase the speed and duration of the immune response, cause only minimal local 
and systemic side effects, and be capable of a wide variety of vaccination with 
stability and ease of production. The ability to be effective in the living system of 
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adjuvants depends on its ability to stimulate antigen-presenting cells (dendritic 
cells and macrophages) and T and B lymphocytes of the natural defense system 
[11]. There is a need for definitive information on the structure, stability, safety 
and immunogenicity of the adjuvant to be used in an effective vaccine development 
process [32, 33]. For this purpose, the choice of adjuvant depends on factors such 
as antigenic structure, immunization scheme, mode of administration and desired 
immune response pattern [33].
2.2.2.1 Nanoparticulate adjuvant systems and DNA vaccine delivery
Nanoparticles are matrix systems called nanospheres or nanocapsules accord-
ing to the method of preparation, which vary in size from 1 to 1000 nm and are 
prepared with natural or synthetic materials. They are also the matrix systems in 
which the active substance nucleic acid is solubilized, adsorbed or electrostatically 
interacted with the surface [23, 45].
In vaccine development studies, nanotechnology is becoming increasingly 
important. Numerous nanoparticles of varying composition, size, shape and 
surface properties are used to both increase vaccine efficacy and target vaccination. 
With these properties, nanoparticles play an active role in in vitro/in vivo drug and 
gene delivery systems. Because nanoparticles are biodegradable and easily recogniz-
able by antigen-presenting cells (APCs), they can be easily endocytosed and used as 
successful vaccine carriers in vaccine delivery systems [22, 25, 40].
Nanoparticle-mediated delivery of DNA vaccines has the advantages of increas-
ing transfection efficiency and immunogenicity, inducing both cellular and anti-
body responses, and not requiring special equipment during administration; there 
are some disadvantages, such as, the long-term effects of nanoparticles in the body 
are not yet known [1]. As a DNA vaccine carrier, natural polymeric nanoparticles 
such as chitosan, alginate, pullulan and inulin (2–1000 nm); synthetic polymeric 
nanoparticles such as PLGA, dendrimer, PLA, PHB and PEI (2–1000 nm); inor-
ganic nanoparticles such as gold, silica-based and carbon-based nanoparticles 
(2–1000 nm); nano-liposomes (100–400 nm) which are phospholipids that can be 
organized in nanoscale and non-infectious virus-like particles (VLP) (20–800 nm) 
generated by packaging the nucleic acid into biocompatible capsid proteins [1, 9, 22]  
are used. In recent years, the use of complex nanoparticles to overcome the disad-
vantages of enhancing the function of single-source nanoparticles has been dis-
cussed. Polyethylene/PLGA, polyg-glutamic acid/chitosan, polyethylene/chitosan, 
dendrimer/polyethylene glycol, polyg-glutamic acid/polyethyleneimine (PEI), 
chitosan/tripolyphosphate and polyethylene glycol/liposome nanoparticles are 
remarkable DNA transport systems [1, 22, 25, 40, 46, 47]. The overall efficiency of 
nanoparticle-based DNA delivery systems depends on four basic factors. These fac-
tors explain the necessity of nanoparticle-based adjuvant systems. Accurate plasmid 
DNA is integrated with the nanoparticle into the target cell correctly, the nanopar-
ticle is removed from the endosomal vesicles and is transferred to the cytoplasm, 
then is transferred to the mitochondria or nucleus [23, 25].
In recent years, there has been a tremendous improvement in the area of gene 
delivery system with the advent of cationic polymers. These polymers bind with 
nucleic acid(s) to form complex structures known as polyplexes, which have 
increased transfection efficiency [10, 48]. Some of the examples of the polycationic 
polymers are chitosan, polyethyleneimine (PEI), poly(2-hydroxy ethyl methacry-
late) (pHEMA), polyamidoamine (PAMAM) dendrimers, polylactic-co-glycolic 
acid (PLGA), polyethylene glycol (PEG) and poly-L-lysine (PLL) and the negatively 
charged phosphate group of pDNA, which have cationic properties. [10, 23, 42, 
43, 49–51]. Many factors such as molecular weight (MW), surface charge, charge 
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density, hydrophilicity and morphology significantly influence the gene transfection 
efficiency of cationic polymers. For this reason, in general, optimization of various 
forms of these cationic polymers with pDNA is required to increase transfection 
efficiency. The polyplex structure electrostatically formed with DNA packs it into 
smaller structure, pDNA, that interacts effectively with the negatively charged cell 
membrane and is endocytosed easily into the cell. In addition, cationic polymers 
are suitable for specific applications like conjugation of targeted ligands and various 
moieties, which provide them with specific characteristics [21, 22, 24, 25, 52].
2.2.2.1.1 Liposomes
Since their discovery in 1964, liposomes are extensively studied and used in the 
pharmaceutical and cosmetic industries. It is a generic name for single- or multi-
lamellar vesicles in lipid-based nano- and micro-dimensions, whose surface charge 
can be changed by lipid formulation. Thanks to biocompatibility, biodegradability, 
low toxicity and low immunogenicity, liposomes have been used as potential nucleic 
acid carriers both in vitro and in vivo systems. In the composition of cationic 
liposomes, neutral lipids, cationic lipids and/or anionic lipids can be complexed in 
different ratios for creating ideal co-lipid. Neutral lipids (DOPE, DPPC, DOPC and 
Chol) are also often involved in the cationic liposome structure for more efficient 
transport systems, although sometimes only cationic lipids (DOTAP, DC-Chol, 
MMRIE, DODAP, DDTAP and DDA) are used [8, 36, 53]. The choice of ideal co-
lipids is important during the formulation phase [54–56], since they significantly 
affect the overall performance of cationic liposomes.
There is a strong correlation between morphology and performance of lipoplex 
(liposome and DNA complex). There are several models that determine morphol-
ogy such as the external model (DNA is attached to the cationic liposome surface), 
the internal model (DNA is surrounded by the cationic liposomes), the cationic 
liposome beads model on the DNA sequence and the spherical model. In addition 
to the liposomal composition, cationic lipid/nucleic acid (N/P) load ratio, prepara-
tion methods, ionic strength and temperature also affect lipoplex formulation and 
morphology. While high N/P ratios accept that the lipid/DNA complex is compatible 
with the global model with effective DNA concentration [22, 54, 57, 58], the low N/P 
ratio accepts the model of cationic liposome beads on the DNA sequence. In addi-
tion, high concentrations of cationic liposomes can cause cytotoxicity. The particle 
size of the lipoplexes is also influential on transfection efficiency. In general, large 
lipoplexes are more effective with in vitro transfection of nucleic acids because large 
pieces allow rapid sedimentation, maximum cell contact with the cell membrane 
and easier separation after endocytosis. Small particles, on the other hand, are much 
more effective, safe and suitable for in vivo transport of nucleic acids [57, 59].
Various studies have shown that cationic liposomes (DC-Chol/DOPE) formed 
at various ratios of 3β-[N-(N′,N′-dimethylaminoethane) carbamoyl] cholesterol 
(DC-Chol) and 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) are 
effective pDNA carriers in the preclinical as well clinical trials for plasmid transfec-
tion [55, 57, 60]. In another study, it was reported that the vaccine adjuvants with 
high immunogenicity were obtained with cationic liposomes formed at 50:50 ratio 
(50 mol%) with DC-Chol/DPPC (3β-[N-(N′,N′-dimethylaminoethane) carbamoyl] 
cholesterol/1,2-dipalmitoyl-sn-glycero-3-phosphocholine) [53]. In many stud-
ies, it has been reported that surface modifications to cationic liposomes (PEG-
polyethylene glycol coating, etc.) increase transfection efficiency due to more stable 
plasmid retention, longer circulation time and lower immunological response. 
Studies have shown that transfection efficiency is increased by about 55% with PEG 
coating to protect surface charges [23, 48, 54, 56, 57, 61].
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2.2.2.1.2 Chitosan
Chitosan is the best-known working polymer among the therapeutic natural 
polymers. It consists of D-glucosamine and N-acetyl-D-glucosamine units linked 
by β-(1,4) glycosidic bonds. The chitosan is derived from the chitin molecule and 
the thermoacetal deacetylation process forms the bonds. The chitin is a biopoly-
mer in abundance in nature and is the cell wall of most of the fungi and bacteria 
of the shellfish and the outer shell of insects [62]. One of the most important 
applications of chitosan is its application as non-viral vector in gene therapy. 
For this reason, chitosan has recently been used for gene delivery systems for 
therapeutic purposes [50, 63]. The first chitosan/DNA complex was made about 
25 years ago, and was composed of plasmid and chitosan in size of 150–600 nm. 
Positive charge, which allows it to complex easily with negatively charged DNA, 
allows the formation of nanocapsules (80–500) at various sizes that protect DNA 
from nuclease activation [64, 65].
Chitosan nanoparticles are formed by a wide variety of methods, by the forma-
tion of different bonds, by different polymer conformations and by various internal 
and external molecular interactions. In addition to covalent cross-linking and 
desolvation methods, ionic gelation is one of the most useful methods used in the 
handling of chitosan nanoparticles and is especially considered for polyelectrolyte 
sodium tripolyphosphate (TPP) [42, 43, 66]. In chitosan-based adjuvants, DNA 
is involved in structure determination, electrostatic interaction, encapsulation 
and surface adsorption [42, 50]. Chitosan has excellent biocompatibility, accept-
able biodegradability, high biosecurity, low cytotoxicity and low immunogenicity. 
However, limited application of gene transport due to poor solubility at physi-
ological pH, insufficient positive charge and low transfection efficiency can be 
prevented by various surface modifications on chitosan nanoparticles [25]. For 
example, TPP is useful in preparing chitosan nanoparticles and enhances its 
non-toxic nature. Due to the self-regulation nature of polycations and polyanions, 
it leads to the formation of linking complexes between TPP groups and chitosan 
amino groups. In the process of the protonation of the chitosan at physiological pH, 
TPP is covalently bound to chitosan amino groups providing structural change and 
better provocation [23, 50, 61, 67, 68].
2.2.2.1.3 Polyethyleneimine (PEI)
Polyethyleneimine is a gene-carrying cationic polymer that has high transfection 
efficiency in vitro and in vivo with lower cost, but can exhibit high toxicity with 
concentration pulse [69–71]. PEI receives proton in aqueous solutions and has a high 
positive charge. Thus, in vitro and in vivo DNA and oligonucleotide transport are 
promising candidates as non-viral transport systems [71, 72]. PEI and its derivatives 
are commonly known as an effective dispersant and cationic flocculent used for 
negatively charged colloids [73].
Adjuvant systems with PEI involve the electrostatic interaction of DNA with the 
cationic polymer and the formation of the polycation/DNA complex [74]. The DNA/
polymer complex (N/P) occurs when the amine group of this polymer interacts with 
the phosphate group of DNA [73]. In many studies, it has been shown that PEI has 
the advantages of holding pDNA with electrostatic bonds, binding to the cell surface 
and its endocytosis, and releasing pDNA into the cell. It also enhances the entry of 
the gene from cytoplasm to the nucleus [70]. This polymer is used for DNA-based 
immunotherapy or DNA vaccine delivery to ensure that the immune response is acti-
vated to provide a strong immune response [74]. Factors such as molecular weight, 
branching grade, ionic strength of solution, zeta potential and particle size affect the 
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efficacy/cytotoxicity of PEI. PEI is coated with PEG and various ligands to increase 
transfection efficiency and reduce cytotoxicity. Meanwhile, the PEI in the linear 
structure helps to create an effective transport system than the branched PEI [69].
2.2.2.1.4 Dendrimers
Dendrimers are nanometer-sized (1–100 nm) particles with a unique architec-
tural structure in the form of spherical macromolecules, consisting of a central 
core, a hyperbranched mantle and a corona containing a peripheral reactive 
group. Dendrimers can be fabricated by convergent or divergent synthesis. The 
high-level control system on dendritic architectural synthesis makes dendrimers 
almost perfect spherical nanostructures with predictable properties. Dendrimers 
can build up ionic interactions with DNA, creating complexes with high stability 
and resolution. Costly production is the only disadvantage. Structures such as 
polyamidoamine and polypropylenimine are included in the dendrimeric clas-
sification [25, 75–78].
Of the cationic compounds used in gene delivery, polyamidoamine (PAMAM) 
dendrimers have been regarded as the most suitable gene carrier, due to the 
presence of abundant amino groups on the electrostatically interacting surface 
with negatively charged nucleic acid material and low polydispersity. This 
association at the nanoscale (nucleic acid-dendrimer pair) is called dendriplex 
[79]. These particular supramolecular structures not only protect the genetic 
material from nuclease degradation but also interact with the negative surface of 
the cell membrane and activate entry into the cell through endocytosis. The high 
amine content of PAMAM dendrimers provides significant buffering capacity in 
the endosomal pH range. This extraordinary buffering capacity plays a power-
ful driving force in the liberation of dendriplex complexes prior to enzymatic 
degradation to lysosomal enzymes in endosomes. These properties make PAMAM 
dendrimers the carriers that are obliged to carry out future polycation-based gene 
delivery studies. On the other hand, long-term storage stability and high bio-
compatibility make PAMAM dendrimers almost necessary to use as gene carriers 
in vivo [24, 25, 49, 51, 61, 75].
The number of generations on the transfection efficiency is important. 
Dendrimer generations G0–G3, low-grade PAMAM dendrimers, exhibit low gene 
transfection efficiency and low cytotoxicity, while G4–G8 dendrimers show high 
transfection efficiency and high cytotoxicity. For this reason, dendrimer genera-
tions G4–G5, which have low cytotoxicity as well as high transfection efficiency in 
gene transfer, are preferred [25, 76]. In addition, adding different moieties enhances 
various features of dendrimers. For example, high amine content on the PAMAM 
surface allows conjugation of various materials to improve transfection efficiency 
and reduce target cytotoxicity [24, 25, 49, 61]. PEG conjugation provides positively 
charged protective sheath, which reduces cytotoxicity, undesired interactions with 
blood components, and facilitates binding of the ligand. Adding hydrophobic 
moieties favors hydrophilic-hydrophobic balance, reduced cytotoxicity and facilita-
tion of packaging back into the vector. With glucocorticoid conjugation, nuclear 
targeting and parental dendrimers (dexamethasone and triamcinolone acetonide 
conjugates) provide hydrophilic-hydrophobic equilibrium modulation. By cyclo-
dextrin conjugation, increase of endosomal escape and decrease of cytotoxicity as 
well as oligonucleotides against enzymatic digestion are protected. Finally, by amino 
acid, peptide and protein conjugation, it is also possible to increase cell penetration 
(arginine and TAT peptide conjugation), cellular uptake, endosomal escape, serum 
resistance (histidine conjugation), and nuclear localization, and also target specific 
receptors [24, 25, 51, 61, 77, 78].
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2.2.2.1.5 Poly(lactic-co-glycolic acid) (PLGA)
PLGA is a solid polymeric material approved by the Food and Drug 
Administration (FDA) for nanoparticle-based drug and gene delivery systems. 
Their biocompatibility, biodegradability, reliability and high stability character-
istics during storage provide advantages in delivery systems [20, 80–82]. PLGA 
nanoparticles can easily pass through vessels in vivo without damaging the tissues 
surrounding the tumor and thus accumulate with the mechanism of “enhanced 
permeability retention” (EPR) in solid tumors. However, PLGA particles are less 
efficient in encapsulating nucleic acids because hydrophobic properties of PLGA are 
not compatible with anionic, hydrophilic properties of nucleic acids. In addition, 
difficult preparation conditions and pH decreases during PLGA hydrolysis inac-
tivate nucleic acid loading and prevent polyplex formation. In order to overcome 
these drawbacks, effective gene transfer systems can be formed with different 
formulations made with different molecular interactions [21, 48, 52, 61, 83–86].
For example, PLGA nanoparticles can be processed with materials such as PEI to 
increase positive charge distribution and provide a stronger penetration of nucleic 
acid. After penetration of the nucleic acids, PEI, PEG cross-linking material and 
cell penetration peptides can be used for effective encapsulation and stabilization of 
the nano-carrier system [48, 81, 85]. It is also one of the systems to produce PLGA-
based adjuvants in sizes of 200–300 nm by such means as cationic hydrophilic 
properties by condensing PLGA with cationic polymers such as polyethylenoxide 
(PEO) and polyethylene glycol methacrylate (PEGMA), emulsifying solvent diffu-
sion method without shear stress [48, 81, 85].
In one study, DNA-loaded PLGA particles were fabricated by a double emul-
sion water in oil in water (w/o/w) method, in which energy is introduced to the 
system typically by either sonication or homogenization, and they were provided 
with submicron size (generally 0.1–10 μm). Then, conjugation of PLL to PLGA 
was achieved through the coupling agent at different percentages to create pDNA/
PLGA/PLL (poly-l-lysine) complex. This system achieved effective gene transport 
by acquiring cationic adjuvant property. [87]. In another study, it has been reported 
that the PLGA particle, which is condensed with the cationic lipid DOTAP, provides 
efficient pDNA encapsulation by forming a cationic adjuvant system [88].
2.2.2.1.6 Polyethylene glycol (PEG)
Polyethylene glycol (PEG) is a highly hydrophilic, non-immunogenic, semi-
crystalline, linear polyether diol used as a non-ionic polymer consisting of ethylene 
oxide monomers. PEG, a polymer approved by the Food and Drug Administration 
(FDA), is non-toxic at low density and does not damage active proteins or cells. 
PEG is excreted completely through the kidneys (<30 kDa PEGs) or stool (>20 kDa 
PEGs) [89]. In addition, functionalities by conjugation of different terminal groups 
such as amino, carboxyl and sulfhydryl groups can be increased. It is soluble in aque-
ous solutions and in most organic solvents like methanol and dichloromethane [89].
The physical properties of the PEG material vary with the molecular weight. 
With an increase in the molecular weight, viscosity of PEG increases, while the 
water solubility decreases. Furthermore, the high solubility of PEG in organic 
solvents provides a great advantage in preparing solid dispersions. PEG provides 
stability to coating particles. The flexibility of the polymer chain, which allows the 
polymer units to rotate freely, ensures that the PEG protects the particles. Thanks 
to its high hydrophilic property, it creates a protective shield around the particulate. 
Nowadays, PEG is used not only to increase stability and circulation time of par-
ticles in vivo, but also to target particles to the desired areas [90].
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In vivo transfection experiments with DC-Chol/DOPE liposomes with 1% PEG 
coating showed that the PEG coating increases the stability and longevity of the 
adjuvant, while it decreases the pH sensitivity and thus decreases the transfection 
rate. This pH sensitivity is important for the vaccination strategies carried out in 
the treatment of an existing tumor tissue [55]. However, there is no indirect disad-
vantage of PEG coating on the transfection rate, as there is no intention to improve 
the present tumor tissue, but there is no need for pH sensitivities for adjuvants in 
vaccine studies designed to protect against tumor formation [23, 54, 56, 61].
2.2.2.1.7 Poly(2-hydroxyethyl methacrylate) (pHEMA)
The pHEMA [poly(2-hydroxyethyl methacrylate)] polymer is the polymerized 
non-toxic form of HEMA (hydroxyethyl methacrylate) which is a toxic monomer. 
Hydrogels are hydrophilic and are capable of holding water up to thousands of times 
more than their own dry mass. For this purpose, pHEMA that is virtually uncharged 
is a three-dimensional hydrophobic polymer that can swell in water or biological 
fluids, and it can be used with a large number of pathways [91, 92]. Because of its 
high water content such as those in body cells, it is used in ureters, cardiovascular 
implants, contact lenses, tissue restorative surgical materials and many dental appli-
cations [93, 94]. pHEMA is also used in the pharmaceutical industry and in tissue 
engineering because of its biocompatibility and similar physical properties as living 
tissues [93]. In addition, the pHEMA polymer has been developed by virtue of its 
high biocompatibility properties and successful complexes formed by a wide variety 
of cationic compounds. It is also used in DNA purification, RNA adsorption and drug 
and enzyme transport [91, 95, 96]. These approaches shed light on the creation of 
new adjuvant systems for the transport of genetic material using pHEMA [91, 93, 97].
In our previous studies, we purposed to develop new pHEMA-based adjuvant 
systems to increase the immune effectiveness and protectivity of the DNA vaccine. 
Within this scope, cationic pHEMA-His/PEG, pHEMA-Chitosan/PEG, pHEMA-PEI/
PEG and pHEMA-DOTAP/PEG particles were developed. As a result, all pHEMA-
based adjuvant systems, which can be produced in nano-sizes and in the desired 
properties, have been shown to increase in vitro transfection efficiency compared 
to naked DNA by using them in different pDNA/adjuvant formulation ratios. When 
compared to Lipofectamine 2000 agent, pHEMA-PEI and pHEMA-DOTAP adjuvant 
formulations are promising candidates for gene transfection agents [98].
2.2.2.2 Characterization of adjuvant systems
Advances in adjuvant systems have led to the development of biodegradable, 
environmentally responsive and biocompatible vaccine carriers (e.g., droplet-based 
microfluidic devices). An ideal adjuvant system should effectively interact with 
both the pDNA and cellular membrane and should not elicit an immune response 
or cytotoxicity. Characterization studies of pDNA vaccine-loaded delivery systems 
are carried out by size and zeta potential measurements, transmission electron 
microscopy (TEM), scanning electron microscopy (SEM), atomic force microscopy 
(AFM), gel retardation assay with agarose gel electrophoresis, PicoGreen assays, 
robustness assays and FT-IR [26, 31, 99–102].
2.3 Cellular uptake of delivery systems
Cellular uptake adjuvant/nucleic acid formulations mainly depend on type, 
size, shape as well as composition, surface chemistry and/or the carrier charge. 
These are key factors, which affect carrier/cell interactions and the transfection 
Immune Response Activation and Immunomodulation
14
efficiency. Cellular uptake of nucleic acid-loaded delivery systems and their 
localization in 2D (monolayer culture) and 3D (multicellular tumor spheroids) 
in vitro cell culture models and also in vivo models are studied by multi-labeling 
3D confocal fluorescence microscopy, flow cytometry, overlaid bright field fluo-
rescence microscopy based on GFP expressions, luciferase assays and fluorescence 
images [26, 27, 100–102].
3. Molecular adjuvants and Bcl-xL anti-apoptotic protein
Molecular adjuvants can be defined as plasmids expressing cytokines, chemo-
kines or co-stimulatory molecules which can be co-administered with the antigenic 
DNA vaccine plasmid [103] or vaccine plasmid can be constructed as a bicistronic 
vector system. The magnitude of immune response after DNA vaccination is 
very closely related to: (i) the source of Ag presentation, (ii) the immunological 
properties of the DNA itself and (iii) the role of cytokines in eliciting the immune 
responses [104]. Thus, with the cells transfected by molecular adjuvant, encoding 
plasmids secrete the adjuvant into the surrounding region stimulating both local 
antigen-presenting cells (APCs) and cells in the draining lymph node, especially 
dendritic cells. The examples of molecular adjuvants as cytokines: GM-CSF (granu-
locyte-macrophage colony stimulating factor), M-CSF, IFN-γ, IL-2, IL-4, IL-7 and 
IL-8, IL-10, IL-12, IL-15, IL-18; as chemokines: IL-8, MCP-1 (monocyte chemoat-
tractant protein 1), MIP-1a (macrophage inflammatory protein), RANTES (CCL5); 
and as co-stimulatory proteins: CD40L, CD80/86, ICAM-1 (intercellular adhesion 
molecule 1) [103]. In addition, ligands of pattern recognition receptors (PRRs) are 
described as molecular adjuvants. There are 13 TLR genes (TLR1–TLR13). TLR3 
and TLR9 recognize dsRNA and ssDNA, respectively, and their ligands have been 
shown to act as molecular adjuvants. Poly(I:C) is a classical TLR3 ligand, and CpG 
is a TLR 9 ligand, showing molecular adjuvant properties via increasing cytotoxic 
T-cell responses [105]. Bcl-xL anti-apoptotic protein was also described as molecu-
lar adjuvant. Inhibiting the apoptosis of antigen-presenting dendritic cells, the 
cytotoxic T-cell responses (CD8+ T cells) are increased due to the longer survival 
of the dendritic cells [106]. In addition, rather than co-transfection, expression of 
Bcl-xL in a bicistronic vector further enhances CD8+ T-cell responses compared to 
co-transfection [107, 108].
In our previous studies, pIRESEGFP/Bcl-xL is a bicistronic vector bearing CMV 
(cytomegalovirus) promoter and IRES (internal ribosomal entry site) used as a 
backbone for DNA vaccination studies. Bcl-xL anti-apoptotic protein in frame 
with eGFP (enhanced green florescence protein) as a molecular adjuvant was also 
encoded by the plasmid. It’s shown that Bcl-xL anti-apoptotic protein rescued cells 
from serum deprivation, doxorubicin, camptothecin and staurosporine induced 
apoptosis [71, 109], induced prolonged expression of the antigen of interest in 
expressed under CMV promoter that facilitates an increased CD8+ T cell response 
in DNA vaccination studies encoding foot and mouth disease multi-epitopes [4] 
and Toxoplasma gondii, SporoSAG antigen [5].
4. Conclusion
In this chapter, we have discussed DNA vaccines, several widely used and 
emerging gene delivery systems to increase efficacy of DNA vaccines, characteriza-
tion of these systems and cellular uptake of DNA vaccines yet to be tested in the 
clinic in the future. Also, as means of molecular adjuvants, several agents are in 
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consideration like chemokines, cytokines, co-stimulatory molecules, PPR ligands 
and anti-apoptotic proteins.
Nanotechnology offers new strategies in formulating better adjuvants for DNA 
vaccines. However, they are very stable and the long-term cytotoxic effects in the 
body appear to be a potential problem. In order to remove this problem, most effec-
tive surface and content modifications of nanoparticles studied are being made. The 
relatively short history of the use of nanoparticles has led to a lack of understanding 
of the safety profile of human use. For this reason, many studies are being carried out 
in this regard today. If a safe profile can be shown as a result of these studies, this new 
vaccine delivery system will be considered to be an effective method, which will be 
widely used. In addition, nanoparticle-based DNA vaccines are seen as a strategy for 
future single-dose applications and the need for needle-free vaccines, as they enhance 
cell transfection efficiency and immunogenicity and enable targeting strategies.
In future studies, the development of nanoparticle-based gene delivery systems 
for different purposes will continue to be critical. Modification of toxicity and 
immunogenicity problems of viral vectors, enhancement of transfection efficiency 
as much as possible for non-viral vectors, enhancement of vector targeting and 
specificity, regulation of gene expression and identification of synergies between 
gene-based agents and other cancer therapies are promising studies. Nevertheless, 
the safe and efficient transport of plasmid DNA to initiate immunological responses 
remains an important barrier to human DNA vaccination. The development of new 
non-viral strategies for DNA vaccines has to continue to serve as biological insight 
and clinic-related methods. Specific concerns include difficulties with transfec-
tion of dendritic cells. This includes methods that target strong antigen signaling, 
antigen-presenting cell uptake and lymph node transduction without sacrificing 
biocompatibility. Carriers must deliver the genetic load specifically to the target 
tissue, while protecting the genetic material from metabolic and immune pathways.
DNA transfection of cells in vitro/in vivo studies requires overcoming both 
extracellular and intracellular barriers to gene transport from cell plasma mem-
brane which is the barrier of intracellular DNA uptake and hinders DNA trafficking 
in the cytoplasm, and also into the cell nucleus that is nuclear envelope. Therefore, 
gene delivery methods including viral, non-viral, physical, chemical and molecular 
systems should facilitate DNA delivery across these barriers and into the nucleus to 
enable transcription without any degradation very quickly. Gene delivery systems 
are so important that besides the characterization of these systems by various meth-
ods such as SEM, TEM, AFM and FT-IR, the examination of their cellular uptake 
by various techniques like confocal complex fluorescence microscopy and flow 
cytometry and the development of study done in this area are extremely important 
in the future.
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